Vis enkel innførsel

dc.contributor.authorMarcon, Alessandroen_US
dc.contributor.authorMarchetti, Pen_US
dc.contributor.authorAnto, J.M.en_US
dc.contributor.authorCazzoletti, Luciaen_US
dc.contributor.authorCerveri, Isaen_US
dc.contributor.authorCorsico, Angeloen_US
dc.contributor.authorFerreira, D.S.en_US
dc.contributor.authorGarcia-Aymerich, Judithen_US
dc.contributor.authorGislason, Daviden_US
dc.contributor.authorHeinrich, Joachimen_US
dc.contributor.authorJögi, Rainen_US
dc.contributor.authorJohannessen, Aneen_US
dc.contributor.authorLeynaert, Benedicteen_US
dc.contributor.authorMalinovschi, Andreien_US
dc.contributor.authorPin, Isabelleen_US
dc.contributor.authorProbst-Hensch, Nicoleen_US
dc.contributor.authorWeyler, Joosten_US
dc.contributor.authorJanson, Christeren_US
dc.contributor.authorJarvis, Deborahen_US
dc.contributor.authorAccordini, Simoneen_US
dc.PublishedMarcon A, Marchetti P, Anto J, Cazzoletti L, Cerveri I, Corsico A, Ferreira, Garcia-Aymerich J, Gislason D, Heinrich J, Jögi R, Johannessen A, Leynaert B, Malinovschi A, Pin I, Probst-Hensch N, Weyler J, Janson C, Jarvis D, Accordini S. Atopy Modifies the Association Between Inhaled Corticosteroid Use and Lung Function Decline in Patients with Asthma.. Journal of Allergy and Clinical Immunology: In Practice. 2020;8(3):980-988.e10eng
dc.description.abstractBackground: Inhaled corticosteroids (ICSs) are the mainstay of asthma treatment, but response to medication is variable. Patients with allergic inflammation generally show a better short-term response to ICSs; however, studies on predictors of long-term response are few. Objective: To assess whether allergic sensitization can modify the association between ICS use and lung function decline over 20 years in adult asthma. Methods: We used data from the 3 clinical examinations of the European Community Respiratory Health Survey. We measured ICS use (no use, and use for <1.3, 1.3-8, and >8 years) and FEV1 decline among subjects with asthma over the 2 periods between consecutive examinations. We conducted a cohort study combining data of the 2 periods (906 observations from 745 subjects) to assess whether the association between ICS use and FEV1 decline was modified by allergic sensitization (IgE > 0.35 kU/L for any of house-dust mite, timothy grass, cat, or Cladosporium). Results: FEV1 decline was similar for non-ICS users, as well as ICS users for less than 1.3 years, with and without allergic sensitization. However, among subjects on ICSs for a longer period, sensitization was associated with an attenuated decline (Pinteraction = .006): in the group treated for more than 8 years, FEV1 decline was on average 27 mL/y (95% CIBonferroni-adjusted, 11-42) lower for subjects with sensitization compared with nonsensitized subjects. Conclusions: Our study suggests that biomarkers of atopy can predict a more favorable long-term response to ICSs. Randomized controlled studies are needed to confirm these findings.en_US
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-NDeng
dc.titleAtopy Modifies the Association Between Inhaled Corticosteroid Use and Lung Function Decline in Patients with Asthmaen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Author(s)
dc.source.journalJournal of Allergy and Clinical Immunology: In Practice

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivs CC BY-NC-ND